Published in J Clin Endocrinol Metab on November 13, 2007
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol (2009) 1.96
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab (2015) 1.24
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 1.23
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med (2012) 1.18
Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis. Am J Hum Genet (2016) 1.15
PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer (2009) 1.11
Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer (2009) 1.05
IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res (2010) 1.03
BRAF inhibitors in clinical oncology. F1000Prime Rep (2013) 0.93
Clinicopathological and molecular histochemical review of skull base metastasis from differentiated thyroid carcinoma. Acta Histochem Cytochem (2013) 0.92
ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer (2013) 0.92
BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract (2012) 0.92
Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol (2011) 0.90
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One (2012) 0.90
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid (2014) 0.89
The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades. Endocrinol Metab (Seoul) (2014) 0.89
Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer. J Clin Endocrinol Metab (2014) 0.87
c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. Mol Med (2012) 0.87
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist (2015) 0.86
Carcinogenesis of PIK3CA. Hered Cancer Clin Pract (2013) 0.83
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR. Thyroid Res (2010) 0.83
Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes (2009) 0.83
Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit. J Clin Endocrinol Metab (2009) 0.80
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. J Transl Med (2016) 0.78
Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer. Int J Clin Exp Pathol (2015) 0.78
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn) (2014) 0.78
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PLoS One (2012) 0.77
ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res (2015) 0.77
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther (2016) 0.77
New insights into the diagnosis of nodular goiter. Thyroid Res (2014) 0.77
Mitochondrial Energy Metabolism and Thyroid Cancers. Endocrinol Metab (Seoul) (2015) 0.76
Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma. BMC Cancer (2016) 0.75
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer (2016) 0.75
Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma. Onco Targets Ther (2016) 0.75
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. J Clin Med Res (2016) 0.75
RASAL1 in thyroid cancer: promise from a new friend. J Clin Endocrinol Metab (2014) 0.75
Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. PLoS One (2016) 0.75
Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS One (2017) 0.75
Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review. Endocr Pathol (2017) 0.75
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet (2009) 1.73
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood (2006) 1.70
Control of histone H3 phosphorylation by CaMKIIδ in response to haemodynamic cardiac stress. J Pathol (2014) 1.47
Colorectal carcinomas from Middle East. Molecular and tissue microarray analysis of genomic instability pathways. Saudi Med J (2008) 1.44
Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol (2002) 1.41
FREM1 mutations cause bifid nose, renal agenesis, and anorectal malformations syndrome. Am J Hum Genet (2009) 1.41
Patterns of Disease in Patients with Middle-Lobe Predominant Bronchiectasis. Respiration (2017) 1.38
Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36
Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther (2008) 1.28
Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol (2011) 1.25
Activation of protein kinase C delta by IFN-gamma. J Immunol (2003) 1.25
Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res (2004) 1.25
Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res (2012) 1.25
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
Poorly differentiated ovarian sertoli-leydig cell tumor in a 16-year-old single woman: a case report and literature review. Case Rep Obstet Gynecol (2013) 1.23
The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail (2014) 1.21
Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol (2009) 1.19
Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One (2012) 1.17
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer (2010) 1.17
The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res (2005) 1.17
High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol (2009) 1.15
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol (2004) 1.15
Malignant glomus tumor (glomangiosarcoma) of intestinal ileum: a rare case report. Case Rep Pathol (2013) 1.15
PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer (2009) 1.11
The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol (2011) 1.09
Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem (2003) 1.06
Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res (2007) 1.06
Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer (2009) 1.05
Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome. Am J Hum Genet (2008) 1.05
Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab (2008) 1.05
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood (2005) 1.03
A missense mutation in PIK3R5 gene in a family with ataxia and oculomotor apraxia. Hum Mutat (2011) 1.02
Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma (2008) 1.01
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol (2009) 1.01
Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest (2010) 1.01
Nodular fasciitis of the breast: a case report. Breast J (2003) 1.00
Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol (2010) 1.00
Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer (2010) 0.99
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res (2008) 0.99
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest (2010) 0.97
Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther (2010) 0.95
Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol (2005) 0.94
Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis (2009) 0.94
Diagnosis by serendipity: Cushing syndrome attributable to cortisol-producing adrenal adenoma as the initial manifestation of multiple endocrine neoplasia type 1 due to a rare splicing site MEN1 gene mutation. Endocr Pract (2008) 0.94
Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. BMC Med Genet (2008) 0.93